Background: Understanding sources of variation in International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores is essential for planning clinical trials in Parkinson's disease and interpreting studies of mild parkinsonian signs. Methods: We describe the characteristics of the MDS-UPDRS in a population-based sample of individuals without parkinsonism. Multiple linear regression and Spearman's rank correlation coefficients were used to examine potential associations. Results: Among 194 consecutive individuals without parkinsonism, the mean total MDS-UPDRS score was 12.5 (SD 9.8). Sixty-nine percent (134/193) had motor examination (Part III) scores of 2 or more, 16% (30/194) had scores of 10 or more. Female sex, arthritis or spondylosis, diabetes mellitus, and essential tremor were found to be associated with statistically significant increases in MDS-UPDRS Part III scores. For every 10-year increase in age, the Part III score was greater on average by 2.2 (1.5-2.8). Conclusions: Elevated MDS-UPDRS scores are common in the general population. The overall burden of motor signs of parkinsonism is especially high in older age groups, in women, and in those with particular comorbidities. Whether this represents evidence of a subclinical neurodegenerative process or the effect of comorbid conditions requires further examination.

Keywords:
Parkinsonism, Mild parkinsonian signs , Epidemiology, Ageing, Parkinson’s disease
1.
Fahn S, Elton RK: Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Goldstein M, Calne DB (eds): Recent Developments in Parkinson's Disease. Florham Park, Macmillan Healthcare Information, 1987, pp 153-163.
2.
Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY: How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012;135:1860-1870.
3.
Louis ED, Bennett DA: Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 2007;22:1681-1688.
4.
Uemura Y, Wada-Isoe K, Nakashita S, Nakashima K: Mild parkinsonian signs in a community-dwelling elderly population sample in Japan. J Neurol Sci 2011;304:61-66.
5.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force: Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
6.
Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG: Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol 2013;260:228-236.
7.
Raina PS, Wolfson C, Kirkland SA, Griffith LE, Oremus M, Patterson C, Tuokko H, Penning M, Balion CM, Hogan D, Wister A, Payette H, Shannon H, Brazil K: The Canadian longitudinal study on aging (CLSA). Can J Aging 2009;28:221-229.
8.
Canadian Longitudinal Study on Aging - Étude longitudinale canadienne sur le vieillissement. www.clsa-elcv.ca (accessed October 21, 2015).
9.
MDS-UPDRS Training Program and Exercise. http://mds.movementdisorders.org/updrs/ (accessed December 16, 2014).
10.
Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
11.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12.
Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R: Association between mild parkinsonian signs and mild cognitive impairment in a community. Neurology 2005;64:1157-1161.
13.
Louis ED, Luchsinger JA, Tang MX, Mayeux R: Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology 2003;61:24-28.
14.
Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA: Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258-266.
15.
Fleischman DA, Wilson RS, Bienias JL, Bennett DA: Parkinsonian signs and cognitive function in old age. J Int Neuropsychol Soc 2005;11:591-597.
16.
Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA: Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol 2003;60:539-544.
17.
Louis ED, Tang MX, Mayeux R: Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol 2004;61:1273-1276.
18.
Wilson RS, Schneider JA, Beckett LA, Evans DA, Bennett DA: Progression of gait disorder and rigidity and risk of death in older persons. Neurology 2002;58:1815-1819.
19.
Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA: Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
20.
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G: MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015;30:1600-1611.
21.
Levy G, Louis ED, Cote L, Perez M, Mejia-Santana H, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Marder K: Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62:467-472.
22.
Lee MS, Lyoo CH, Ryu YH, Lim HS, Nam CM, Kim HS, Rinne JO: The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease. Acta Neurol Scand 2011;124:196-201.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.